Signaling networks assembled by oncogenic EGFR and c-Met.
about
Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactomeA secreted tyrosine kinase acts in the extracellular environmentConstitutive activated Cdc42-associated kinase (Ack) phosphorylation at arrested endocytic clathrin-coated pits of cells that lack dynaminDifferential 14-3-3 affinity capture reveals new downstream targets of phosphatidylinositol 3-kinase signalingEGFR/Met association regulates EGFR TKI resistance in breast cancerAn overview of the c-MET signaling pathwayThe impact of microRNAs on protein outputSelective Sensing of Tyrosine Phosphorylation in Peptides Using Terbium(III) ComplexesProtein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerAnalysis of oncogenic signaling induced by tyrosine kinases in tumors by SILAC-based quantitative proteomic approachPost-translational modifications of intermediate filament proteins: mechanisms and functionsRole of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agentsCharacterizing tyrosine phosphorylation signaling in lung cancer using SH2 profilingNeuroblastoma tyrosine kinase signaling networks involve FYN and LYN in endosomes and lipid raftsAssessment, origin, and implementation of breath volatile cancer markers.Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A ReviewBiology of MET: a double life between normal tissue repair and tumor progressionTyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activityPTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRSystems Proteomics View of the Endogenous Human Claudin Protein FamilySticky signaling--adhesion class G protein-coupled receptors take the stageNorcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cellsReceptor tyrosine kinase (RTK) mediated tyrosine phosphor-proteome from Drosophila S2 (ErbB1) cells reveals novel signaling networksCombined drug action of 2-phenylimidazo[2,1-b]benzothiazole derivatives on cancer cells according to their oncogenic molecular signaturesGefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationSH3 interactome conserves general function over specific form.Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Src-dependent tyrosine phosphorylation of non-muscle myosin heavy chain-IIA restricts Listeria monocytogenes cellular infectionThe MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion.Reconstructing targetable pathways in lung cancer by integrating diverse omics dataAberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607.Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.Mass spectrometry identifies multiple organophosphorylated sites on tubulin.Structural models of human eEF1A1 and eEF1A2 reveal two distinct surface clusters of sequence variation and potential differences in phosphorylation.In-depth qualitative and quantitative profiling of tyrosine phosphorylation using a combination of phosphopeptide immunoaffinity purification and stable isotope dimethyl labelingClinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.Novel Ser/Thr protein phosphatase 5 (PP5) regulated targets during DNA damage identified by proteomics analysis.
P2860
Q24294625-B540A7EE-EF51-4C58-9E8F-C2905BE86872Q24303065-D8E02F85-A2BA-450E-A6AB-5FCA6019B0A5Q24317755-E1F7EE4A-C39D-431C-A13B-F77EC4CCC3E4Q24319111-AA528B8F-F728-4B62-9610-623AA55CB592Q24338635-F4ED1BAC-1DF5-4C4A-87CB-0F9E37B81316Q24633986-6DFD1A64-A01F-4E2D-B82C-00F6764198EAQ24653549-2D8DC8D4-30E1-46D7-BBBB-A95025AA65A6Q26744839-5010E95B-8894-4D0D-BC1C-C191B06621FDQ26852215-51C5F372-5AC7-4EB4-B57A-5D8B57B1F0A3Q26852884-F820BDC5-2823-4B41-9F76-3F12CA1AC421Q27004670-0D185D18-FC19-42DD-8D22-6E887CD5FB6FQ27027957-C6E19FE6-7F67-45A0-9A7B-962D49A232AEQ27317429-5DAE1DD9-2160-4F55-A18E-2F9B7AF37FC7Q27319837-68594A14-6941-45CE-B785-0F339A3D26F0Q27692565-1E81FDAB-18C0-467B-A27F-11DBC8959DE2Q28074119-38C0EA00-F0ED-4DB7-A4CE-CEA981893C4DQ28085247-28361EAC-CAD7-4197-BC59-C8C9A24CAC38Q28115584-CD7A8244-984B-44BA-A355-080764991E1CQ28240702-D2A73C62-6C4D-4B45-A25E-9A4180932AE4Q28271194-B93FE7B2-4AC4-4C98-BB7C-6FF627A9D58FQ28291130-F5DD8E10-47C9-4187-9935-A9D3AEE4C7BAQ28468579-1BF98906-0C8D-4EB0-B535-32EFCF3FEE93Q28473351-D80587BB-A058-4D27-A52A-F7E2D6E644E5Q28484238-2567C8A5-5C75-4FC5-A79E-FCFD2DA919F2Q28534577-B97FC5C5-1FAC-4107-AC8D-27B0AC144BF2Q30009888-FBFA346B-A081-44AF-BB39-01DCA6199A6BQ30278774-8F0AA130-418B-406D-B411-AFBD214CF0ABQ30360087-8C2FFD96-6C6C-4636-8456-F81ECB4665C8Q30494514-2C98E537-795F-4AAD-A0D6-DB3ACBD1C378Q30537354-BCB6966D-2EC2-4C5A-81A1-B3A6D00424AAQ30679547-5D4D807B-6112-45D4-BA8F-6336CBE79D55Q30931456-F589C43C-533B-493B-AF74-EE518814D71AQ31062741-350B25B2-970B-4069-BCE4-6893CDD6AABAQ33411775-E3439DC3-D1D3-418F-BF39-2200DB5E86D2Q33486958-4755D72E-F6FF-4417-B126-E937E25D61E1Q33487694-E09549C8-9C4F-47F7-81A1-4E6DD240C059Q33598027-CFCA051B-0D74-4B35-91B2-7756708AACA4Q33602552-EED34AB1-1FDE-4521-8B95-DB145A960874Q33614314-D482ABEB-981D-4009-8426-C8D17B135242Q33639959-8256D0D8-F7B4-4C02-98DD-8A4A59D67813
P2860
Signaling networks assembled by oncogenic EGFR and c-Met.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Signaling networks assembled by oncogenic EGFR and c-Met.
@ast
Signaling networks assembled by oncogenic EGFR and c-Met.
@en
type
label
Signaling networks assembled by oncogenic EGFR and c-Met.
@ast
Signaling networks assembled by oncogenic EGFR and c-Met.
@en
prefLabel
Signaling networks assembled by oncogenic EGFR and c-Met.
@ast
Signaling networks assembled by oncogenic EGFR and c-Met.
@en
P2093
P2860
P356
P1476
Signaling networks assembled by oncogenic EGFR and c-Met.
@en
P2093
Anthony Possemato
Gregory Innocenti
Jeffrey Mitchell
Joan MacNeill
Jon Kornhauser
Julie Nardone
Kimberly A Lee
Klarisa Rikova
P2860
P304
P356
10.1073/PNAS.0707270105
P407
P577
2008-01-07T00:00:00Z